GMAB – Genmab A/S
GMAB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.6
Margin Of Safety %
Put/Call OI Ratio
0.3
EPS Next Q Diff
-0.26
EPS Last/This Y
-0.31
EPS This/Next Y
0.51
Price
51.72
Target Price
63.38
Analyst Recom
1.57
Performance Q
61.99
Upside
-20.9%
Beta
0.71
Ticker: GMAB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-14 | GMAB | 36.9 | 0.29 | 0.37 | 100722 |
| 2026-10-15 | GMAB | 37.82 | 0.29 | 0.05 | 101372 |
| 2026-10-16 | GMAB | 36.99 | 0.29 | 1.81 | 102174 |
| 2026-10-19 | GMAB | 38.5 | 0.27 | 0.31 | 95179 |
| 2026-10-20 | GMAB | 39.07 | 0.26 | 0.93 | 94759 |
| 2026-10-21 | GMAB | 39.6 | 0.29 | 1.97 | 100147 |
| 2026-10-22 | GMAB | 39.99 | 0.30 | 2.39 | 100693 |
| 2026-10-23 | GMAB | 43.8 | 0.31 | 5.00 | 101885 |
| 2026-10-26 | GMAB | 44.69 | 0.31 | 0.43 | 102039 |
| 2026-10-27 | GMAB | 44.69 | 0.32 | 0.03 | 86551 |
| 2026-10-28 | GMAB | 57.33 | 0.27 | 0.25 | 101017 |
| 2026-10-29 | GMAB | 56.47 | 0.34 | 0.53 | 114158 |
| 2026-10-30 | GMAB | 57.02 | 0.35 | 0.10 | 118857 |
| 2026-11-02 | GMAB | 54.93 | 0.33 | 0.17 | 127168 |
| 2026-11-03 | GMAB | 55.52 | 0.32 | 0.08 | 131373 |
| 2026-11-04 | GMAB | 55.09 | 0.32 | 0.13 | 131373 |
| 2026-11-05 | GMAB | 52.69 | 0.32 | 0.28 | 134618 |
| 2026-11-06 | GMAB | 53.62 | 0.32 | 0.09 | 134476 |
| 2026-11-09 | GMAB | 55.8 | 0.32 | 0.03 | 134611 |
| 2026-11-10 | GMAB | 54.08 | 0.30 | 0.05 | 145086 |
| 2026-11-11 | GMAB | 53.87 | 0.30 | 0.59 | 145581 |
| 2026-11-12 | GMAB | 51.69 | 0.30 | 0.09 | 145156 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-14 | GMAB | 36.89 | - | 527.8 | 1.17 |
| 2026-10-15 | GMAB | 37.83 | - | 552.5 | 1.17 |
| 2026-10-16 | GMAB | 37.00 | - | 486.9 | 1.17 |
| 2026-10-19 | GMAB | 38.50 | - | 578.0 | 1.17 |
| 2026-10-20 | GMAB | 38.50 | - | 578.0 | 1.17 |
| 2026-10-21 | GMAB | 39.07 | - | 566.8 | 1.17 |
| 2026-10-22 | GMAB | 40.01 | - | 543.3 | 1.17 |
| 2026-10-23 | GMAB | 43.79 | - | 668.4 | 1.17 |
| 2026-10-26 | GMAB | 44.69 | - | 567.7 | 1.17 |
| 2026-10-27 | GMAB | 44.66 | - | 532.7 | 1.17 |
| 2026-10-28 | GMAB | 57.34 | - | 961.1 | 1.17 |
| 2026-10-29 | GMAB | 56.47 | - | 505.7 | 1.17 |
| 2026-10-30 | GMAB | 57.04 | - | 541.4 | 1.17 |
| 2026-11-02 | GMAB | 54.93 | - | 475.8 | 1.17 |
| 2026-11-03 | GMAB | 55.49 | - | 490.1 | 1.17 |
| 2026-11-04 | GMAB | 55.08 | - | 521.4 | 1.17 |
| 2026-11-05 | GMAB | 52.73 | - | 470.7 | 1.17 |
| 2026-11-06 | GMAB | 53.63 | - | 586.7 | 1.17 |
| 2026-11-09 | GMAB | 55.81 | - | 630.1 | 1.17 |
| 2026-11-10 | GMAB | 54.08 | - | 515.6 | 1.17 |
| 2026-11-11 | GMAB | 53.87 | - | 550.5 | 1.24 |
| 2026-11-12 | GMAB | 51.72 | - | 500.8 | 1.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-14 | GMAB | 0.00 | 0.35 | 1.03 |
| 2026-10-15 | GMAB | 0.00 | 0.35 | 1.03 |
| 2026-10-16 | GMAB | 0.00 | 0.35 | 1.03 |
| 2026-10-19 | GMAB | 0.00 | 0.25 | 1.03 |
| 2026-10-20 | GMAB | 0.00 | 0.25 | 1.03 |
| 2026-10-21 | GMAB | 0.00 | 0.25 | 1.03 |
| 2026-10-22 | GMAB | 0.00 | 0.25 | 1.03 |
| 2026-10-23 | GMAB | 0.00 | 0.25 | 1.03 |
| 2026-10-26 | GMAB | 0.00 | 0.29 | 1.03 |
| 2026-10-27 | GMAB | 0.00 | 0.29 | 1.12 |
| 2026-10-28 | GMAB | 0.00 | 0.29 | 1.12 |
| 2026-10-29 | GMAB | 0.00 | 0.29 | 1.12 |
| 2026-10-30 | GMAB | 0.00 | 0.29 | 1.12 |
| 2026-11-02 | GMAB | 0.00 | 0.25 | 1.12 |
| 2026-11-03 | GMAB | 0.00 | 0.25 | 1.12 |
| 2026-11-05 | GMAB | 0.00 | 0.25 | 1.12 |
| 2026-11-06 | GMAB | 0.00 | 0.25 | 1.12 |
| 2026-11-09 | GMAB | 0.00 | 0.19 | 0 |
| 2026-11-10 | GMAB | 0.00 | 0.19 | 1.09 |
| 2026-11-11 | GMAB | 0.00 | 0.19 | 1.60 |
| 2026-11-12 | GMAB | 0.00 | 0.19 | 1.60 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.56
Avg. EPS Est. Current Quarter
0.16
Avg. EPS Est. Next Quarter
0.3
Insider Transactions
Institutional Transactions
0.19
Beta
0.71
Average Sales Estimate Current Quarter
1249
Average Sales Estimate Next Quarter
1051
Fair Value
51.94
Quality Score
89
Growth Score
97
Sentiment Score
89
Actual DrawDown %
13.8
Max Drawdown 5-Year %
-61.8
Target Price
63.38
P/E
44.33
Forward P/E
31.54
PEG
1.49
P/S
7.41
P/B
5.02
P/Free Cash Flow
37.38
EPS
1.17
Average EPS Est. Cur. Y
1.24
EPS Next Y. (Est.)
1.75
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
16.96
Relative Volume
1.34
Return on Equity vs Sector %
-14.9
Return on Equity vs Industry %
4.6
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.11
EBIT Estimation
500.8
◆
GMAB
Healthcare
$51.74
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
60.2
Range 1M
66.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-18.2%
EPS NY
30.5%
52W%
77.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+13.8% upside
Upside
+13.8%
Quality
89
MoS
0%
GMAB — P/E HistoricalBiotechnology
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 3244
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
GMAB
Latest News
—
Caricamento notizie per GMAB…
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading